ArticleAnalytical and bioanalytical chemistry2026
Accelerating microfluidic capillary electrophoresis-mass spectrometry for charge-variant and glycoform analysis of intact monoclonal antibodies.
Article in Analytical and bioanalytical chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Scientific and operational maturity of CE-MS: are we close?Trends in biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The analytical determination of critical quality attributes (CQAs) of monoclonal antibodies (mAbs) is often time-consuming. Hence, increasing analysis throughput can shorten biopharmaceutical development timelines and enables rapid decision-making. Microfluidic capillary electrophoresis coupled to mass spectrometry (MCE-MS) allows fast analysis of charge variants and glycoforms of mAb samples. In a recently published MCE-MS method, we used a microfluidic chip with a 22-cm separation channel length, permitting analysis of 96 samples per day. To further increase the throughput of the method and better meet the needs of the biopharmaceutical industry, we propose the use of a chip with a distinctly shorter channel length (10 cm). However, a substantial drop in electrophoretic resolution was observed due to the increased laminar flow caused by the pressure put on the shortened channel during analysis. To mitigate this phenomenon, the MCE setup was modified to allow independent adjustment of the gas pressure on the separation channel inlet. The mAb charge-variant resolution significantly improved by reducing the inlet pressure from 2.0 to 0.75 psi. The performance of the modified setup was assessed by analysis of mAb samples from cell lines, mimicking a typical biosimilar clone screening. The original (22-cm channel, 2.0 psi on inlet) and modified (10-cm channel, 0.75 psi on inlet) setups yielded comparable separation profiles and number of MS-identified proteoforms across all clone mAbs. Overall, the new MCE-MS method reduces total analysis time per sample by 3.3-fold, which conceptually facilitates the analysis of more than 300 samples per day with minimal loss in separation performance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.